Please assess the completion status of the following clinical trial:

Trial Title: Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes Mellitus~* Dyslipidemia~* Undergoing elective PCI~Exclusion Criteria:~* Patients with recent Acute Coronary Syndrome (≤1 month)~* Patients on dual antiplatelet treatment (DAPT) with ticagrelor or prasugrel~* Patients undergoing urgent/emergent PCI for stent thrombosis~* Severe acute or chronic medical or psychiatric condition~* Pregnancy~* Participation in another experimental clinical trial, without formal approval~* Unwillingness or inability to comply with the requirements of this protocol

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- evolocumab 420mg (Type: ACTIVE_COMPARATOR): 75 subjects on optimal statin therapy undergoing elective PCI will receive evolocumab 420mg.
- placebo (Type: PLACEBO_COMPARATOR): 75 subjects on optimal statin therapy undergoing elective PCI will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).